Results 81 to 90 of about 4,766 (189)

Concentration-time profiles for the accumulation of elvitegravir in U1 cells with or without cobicistat and ethanol.

, 2017
Results expressed as means ± SEM of the cellular concentrations measured (μM/mg of protein). EVG, Elvitegravir; COBI, Cobicistat; EtOH, ethanol.
Pradeep B. Lukka (3775327), Santosh Kumar (106550), Bernd Meibohm (110267), Narasimha M. Midde (309014), Namita Sinha (724836)   +4 more
core   +1 more source

Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults

Pulmonary Circulation, 2019
Riociguat, a first-in-class soluble guanylate cyclase stimulator, is approved for the treatment of pulmonary arterial hypertension (PAH), a serious potential complication of human immunodeficiency virus (HIV) infection. This open-label study investigated
Edwin DeJesus, Soundos Saleh, Sue Cheng, Dorina van der Mey, Corina Becker, Reiner Frey, Sigrun Unger, Wolfgang Mueck   +7 more
doaj   +1 more source

Intracellular elvitegravir concentration in the presence of MRP1 or MDR1 inhibitors and cobicistat + ethanol.

, 2017
EVG quantified from cell lysates using LC MS/MS after 24 hours treatment with indicated drugs. Data are expressed as mean ± SEM from 3 independent experiments. *p< 0.05 compared to EVG+COBI+EtOH (Control).
Pradeep B. Lukka (3775327), Santosh Kumar (106550), Bernd Meibohm (110267), Narasimha M. Midde (309014), Namita Sinha (724836)   +4 more
core   +1 more source

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

, 2012
Background: Elvitegravir is a once daily inhibitor of HIV-1 integrase boosted by ritonavir. We aimed to compare the efficacy and safety of elvitegravir with raltegravir, another HIV-1 integrase inhibitor, in patients in whom previous antiretroviral ...
Chuck SL, Jean-Michel Molina, Chuck, Steven L, Jaime Andrade-Villanueva, Lijie Zhong, Study 145 Team, Ya-Pei Liu, LaMarca, A., Clotet, Bonaventura, Cheng, A.K., Lamarca A, Margot, N., Liu YP, Nathan Clumeck, Clumeck, Nathan, Cheng, Andrew K, Clotet, B., Zhong, L., Margot, Nicolas, Clumeck, N., Liu, Y.-P., Nicolas Margot, VULLO, Vincenzo, Andrade-Villanueva, J., Margot N, Andrade-Villanueva, Jaime, Clumeck N, Molina, Jean-Michel, Andrew K Cheng, Liu, Ya-Pei, Anthony LaMarca, Molina, J.-M., Molina JM, Andrade Villanueva J, Lamarca, Anthony, Chuck, S.L., Clotet B, Zhong, Lijie, Bonaventura Clotet, Steven L Chuck, Cheng AK, Zhong L   +41 more
core   +1 more source

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study

Infectious Diseases and Therapy, 2019
Introduction Dolutegravir (DTG), Elvitegravir (EVG), Raltegravir (RAL) and Darunavir (DRV) are commonly prescribed core agents for antiretroviral therapy (ART), and a need exists to compare their clinical effectiveness, as defined by virologic failure ...
Anthony M. Mills, Laurence Brunet, Jennifer S. Fusco, Michael B. Wohlfeiler, Cindy P. Garris, Alan K. Oglesby, Joseph M. Mrus, Philip C. Lackey, Gregory P. Fusco   +8 more
doaj   +1 more source

HIV–1 resistance to dolutegravir: update and new insights

Journal of Virus Eradication, 2015
Integrase strand transfer inhibitors (INSTIs) are the latest class of potent anti-HIV drugs. Currently, three INSTIs have been approved by the US Food and Drug Administration: raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG).
Mark A. Wainberg, Ying-Shan Han
doaj   +1 more source

In vitro antibacterial activity of antiretroviral drugs on key commensal bacteria from the human microbiota

Frontiers in Cellular and Infection Microbiology
IntroductionAntiretroviral therapy has improved life expectancy in HIV-infected patients. However, people living with HIV under antiretroviral therapy are at higher risks of developing chronic complications and acquiring multidrug resistant bacteria than
Elisa Rubio-Garcia, Elisa Rubio-Garcia, Elisa Rubio-Garcia, Elisa Rubio-Garcia, Núria Ferrando, Núria Martin, Clara Ballesté-Delpierre, Clara Ballesté-Delpierre, Jose M. Miró, Jose M. Miró, Roger Paredes, Roger Paredes, Roger Paredes, Roger Paredes, Climent Casals-Pascual, Climent Casals-Pascual, Climent Casals-Pascual, Climent Casals-Pascual, Jordi Vila, Jordi Vila, Jordi Vila, Jordi Vila   +21 more
doaj   +1 more source

The role of cytochrome P450 2E1 on ethanol-mediated oxidative stress and HIV replication in human monocyte-derived macrophages

Biochemistry and Biophysics Reports, 2019
Background: Alcohol consumption is considered to be a major health problem among people living with HIV/AIDS. Our previous reports have shown that ethanol reduced intracellular concentrations of antiretroviral drugs elvitegravir and darunavir in the HIV ...
Yuqing Gong, P.S.S. Rao, Namita Sinha, Sabina Ranjit, Theodore J. Cory, Santosh Kumar   +5 more
doaj   +1 more source

Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection

Therapeutics and Clinical Risk Management, 2009
Christine Katlama, Robert MurphyPierre et Marie Curie Universit&eacute; &ndash; Paris 6, Service de Maladies Infectieuses et Tropicales, Paris, FranceAbstract: Integrase is an essential HIV-1-specific enzyme that is an active target for ...
Christine Katlama, Robert Murphy
doaj  

Matrix effect (ME), recovery (RE) and process efficiency (PE) of elvitegravir (EVG) (n = 6).

, 2016
Matrix effect (ME), recovery (RE) and process efficiency (PE) of elvitegravir (EVG) (n = 6).
Mohammad A. Rahman (1806823), Chetan Rathi (1806826), Weihua Li (144468), Santosh Kumar (106550), Bernd Meibohm (110267), Junhao Li (844050), Narasimha M. Midde (309014)   +6 more
core